Research and Markets: Hospital Care Partnering Yearbook 2013: Understand the partnering deals and agreements entered into by the worlds leading healthcare companies
<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: , </0>
() has announced the addition of the report to their offering.
The Hospital Care Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012.
Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.
The initial chapters of this report provide an orientation of 2012's dealmaking and business activities.
Chapter 1 provides an overview of the trends in dealmaking during 2012 covering trends by deal type, stage of development, technology type and therapeutic indication.
Chapter 2 provides a review of the leading deals during 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all partnering deals announced during 2012.
The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.
- Abbott
- Actavis
- Actelion
- Allergan
- Amgen
- Aspen Pharmacare
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Endo Pharmaceuticals
- Forest Laboratories
- Galderma
- Gilead Sciences
- GlaxoSmithKline
- Grifols
- Hospira
- Johnson & Johnson
- Kyowa Hakko Kirin
- Lundbeck
- Menarini
- Merck & Co
- Merck KGaA
- Mitsubishi Tanabe
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Purdue
- Roche
- Sanofi
- Servier
- Shionogi
- Shire
- Takeda
- Teva
- Valeant
- Warner Chilcott
- Watson